Molina (MOH) Q1 2026 Earnings Transcript

Molina Healthcare reported Q1 adjusted EPS of $2.35 on $10.2 billion of premium revenue, with consolidated MCR at 91.1% and guidance reaffirmed for full-year 2026 revenue of about $42 billion and EPS of at least $5. The quarter was solid, but management stayed cautious, citing Medicaid membership attrition rising to 6% from 2% and delaying any guidance lift until more data is available. Offset factors include strong parent cash generation, improving Medicare duals performance, and a sizable Florida CMS Kids contract that management says adds meaningfully to embedded earnings.

Analysis

The setup is better than the reported optics suggest: the business is being de-risked in exactly the segment mix that caused the market to over-penalize managed care in 2025. The key second-order effect is that Medicaid attrition is no longer automatically bearish if the lost lives are disproportionately low-utilization and the offset comes from a higher-margin, more predictable Marketplace book; that combination should compress the dispersion of forward estimates and lower the probability of another “accrual shock” quarter.

The bigger underappreciated lever is 2027 earnings power. Exiting the MAPD business removes a clear drag, while the Florida contract and the integrated duals conversion create a cleaner earnings bridge that is not fully visible in current guidance. If management is right that acuity normalization is largely done, then the market is still valuing MOH off a near-term margin ceiling that may not exist; the optionality is in state rate catch-up and embedded earnings conversion, both of which can expand EPS faster than headline premium growth.

The main risk is timing, not direction: 2Q and 3Q will need to prove that Q1 was not just favorable seasonality plus payment timing. Another risk is political: work requirements, redeterminations, and state implementation noise could create member churn without immediate rate relief, which would pressure multiples even if actuarial losses remain contained. So the stock should trade more like a catalyst-driven rerate than a steady compounder until Investor Day and the next two quarters validate the new baseline.

Contrarian angle: the consensus is likely overweighting Medicaid headcount and underweighting capital structure flexibility. Parent cash is the real constraint, and once that normalizes while debt metrics stay inside tolerance, MOH has room to accelerate buybacks or bolt-on deals; that creates a hidden floor under 2027 EPS even if top-line growth stays modest. The market may also be missing that removing MAPD simplifies the story enough to lift the multiple regardless of modest near-term guidance conservatism.

Key Decisions for Investors

• Long MOH into Investor Day (May 8) and Q2 print: use a 3-6 month horizon; thesis is rerating on 2027 earnings clarity and MAPD exit. Risk/reward favors buying on any post-call consolidation rather than chasing strength.
• Structure a bullish options trade on MOH: buy 6-9 month call spreads to capture the potential multiple expansion without overpaying for volatility. Best if the stock stalls ahead of the next guidance update.
• Pair trade: long MOH / short a higher-regulatory-risk Medicaid-managed-care basket (preferably a peer with heavier redetermination exposure). This isolates the relative advantage of MOH’s duals/Marketplace mix and embedded earnings conversion.
• If holding MOH outright, set a tight stop around any evidence in Q2 of rising medical trend or renewed acuity shift. The stock is most vulnerable if the market concludes Q1 was timing-driven rather than structural.
• Add on weakness if parent cash and debt trajectory remain on track in the next update; that is the cleanest catalyst for capital-return upside and a higher terminal multiple.